Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | AHR | P35869 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9219681 | 0.78 | GPR84 (0.61) | GPR84MEN1KMT2ACYP3A4MAPT | |
| Arundine SCHEMBL325162 | 0.74 | MEN1 (1.00) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL2793555 | 0.74 | GPR84 (0.59) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL16431196 | 0.73 | GPR84 (0.69) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL20204745 | 0.72 | GPR84 (0.57) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL21366323 | 0.72 | GPR84 (0.54) | GPR84MEN1KMT2ACYP3A4MAPT | |
| Arundine SCHEMBL28335217 | 0.72 | MEN1 (0.95) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL12559876 | 0.72 | GPR84 (0.61) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL31744758 | 0.71 | GPR84 (0.65) | GPR84MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL735576 | 0.71 | GPR84 (0.65) | GPR84MEN1KMT2ACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940787-A4 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INST MEDICAL RES (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1940787-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | Lankenau Institute for Medical Research (US) | 2008-07-09 | — | — | EP | claimed |
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-10 | — | — | US | claimed |
| WO-2007050963-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-05-03 | — | — | WO | claimed |
| US-20100166881-A1 | Novel IDO Inhibitors and Methods of Use Thereof | PRENDERGAST GEORGE C | 2010-07-01 | — | — | US | disclosed |
| US-7705022-B2 | N-[2-(Indol-3-yl)ethyl]-S-methyl-dithiocarbamate; N-[2-(benzo[b]thiophen-3-yl)ethyl]-S-methyl-dithiocarbamate; N-[2-(indol-3-yl)ethyl]-S[(naphth-2-yl)methyl]-dithiocarbamate; anticarcinogenic agents; free of brassinin | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1940787-A4 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INST MEDICAL RES (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1940787-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | Lankenau Institute for Medical Research (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-10 | — | — | US | disclosed |
| WO-2007050963-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE THEREOF | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166881-A1 | Novel IDO Inhibitors and Methods of Use Thereof | IDO1, IDO2, INMT | GPR84 2388/4885MEN1 4332/4885KMT2A 845/4885 |
| US-20070105907-A1 | Novel IDO inhibitors and methods of use thereof | IDO1, IDO2, INMT | GPR84 2388/4885MEN1 4332/4885KMT2A 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.